TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)
STOCKS

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

  • By Adam Feuerstein
  • Dec 22, 2016 11:20 AM EST
PRESS RELEASES

Ampio Provides Update On Clinical Trials For Ampion™ Treatment Of COVID-19 Patients

  • By PR Newswire
  • Jan 4, 2021 9:15 AM EST
PRESS RELEASES

Ampio Receives Feedback From The FDA On Ampio's Proposed Modifications To The Special Protocol Assessment For Ampion Treatment Of Severe Osteoarthritis Of The Knee

  • By PR Newswire
  • Dec 29, 2020 9:15 AM EST
PRESS RELEASES

Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

  • By PR Newswire
  • Dec 17, 2020 9:15 AM EST
PRESS RELEASES

Ampio Enters Into Collaborative Research Agreements To Explore Additional Clinical Indications For Its Immunomodulatory Drug, Ampion

  • By PR Newswire
  • Dec 10, 2020 9:15 AM EST
PRESS RELEASES

Ampio Pharmaceuticals, Inc. To Host Its Annual Meeting On December 12, 2020

  • By PR Newswire
  • Dec 8, 2020 9:15 AM EST
PRESS RELEASES

Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress

  • By PR Newswire
  • Dec 2, 2020 9:15 AM EST
PRESS RELEASES

Ampio Updates Regulatory And Clinical Trial Events

  • By PR Newswire
  • Nov 25, 2020 9:15 AM EST
PRESS RELEASES

Ampio's Phase I Study For Inhaled Ampion Advances To 3rd Group Of COVID-19 Patients With Respiratory Distress

  • By PR Newswire
  • Nov 17, 2020 9:15 AM EST
PRESS RELEASES

Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress

  • By PR Newswire
  • Nov 10, 2020 4:01 PM EST
PRESS RELEASES

Ampio Pharmaceuticals, Inc. Provides Business Update And Reports Third Quarter 2020 Financial Results

  • By PR Newswire
  • Nov 5, 2020 3:45 PM EST
PRESS RELEASES

Ampio Pharmaceuticals, Inc. To Host Conference Call On November 5th

  • By PR Newswire
  • Nov 2, 2020 9:15 AM EST
PRESS RELEASES

Ampio Begins Phase 1 Clinical Trial Of Inhaled Ampion For COVID-19 Patients With Respiratory Distress

  • By PR Newswire
  • Oct 28, 2020 7:30 AM EDT
PRESS RELEASES

Ampio Pharmaceuticals, Inc. To Present At The ROTH Capital Healthcare Event "COVID-19 Therapeutics In Development"

  • By PR Newswire
  • Oct 27, 2020 9:15 AM EDT
PRESS RELEASES

Ampio Presents At Roth Capital Partners 2020 MedTech Innovation Forum Focusing On COVID-19 Clinical Trial Activities

  • By PR Newswire
  • Oct 26, 2020 9:15 AM EDT
PRESS RELEASES

Ampion Phase I COVID-19 Patient Trial Results Featured On FOX News (Video)

  • By PR Newswire
  • Sep 14, 2020 9:15 AM EDT
PRESS RELEASES

Ampio Reports Positive Results For Ampion Treatment In COVID-19 Patients

  • By PR Newswire
  • Sep 9, 2020 9:15 AM EDT
PRESS RELEASES

Ampio Announces Enrollment Completion For Intravenous ("IV") COVID-19 Clinical Trial & Provides Update On Osteoarthritis Of The Knee ("OAK") Clinical Trial

  • By PR Newswire
  • Sep 4, 2020 9:15 AM EDT
PRESS RELEASES

Ampio Provides Update On COVID-19 Clinical Trial Activities

  • By PR Newswire
  • Aug 19, 2020 8:00 AM EDT
PRESS RELEASES

Ampio Starts Patient Enrollment In Its Ampion COVID-19 Program

  • By PR Newswire
  • Jul 23, 2020 8:00 AM EDT
PRESS RELEASES

Ampio Reports A Publication On The Potential Benefits Of Ampion For Treatment Of A New COVID-19 Related Syndrome

  • By PR Newswire
  • Jul 20, 2020 8:00 AM EDT
PRESS RELEASES

Ampio To Start First Clinical Trial In COVID-19 Program

  • By PR Newswire
  • Jun 19, 2020 8:00 AM EDT
PRESS RELEASES

Ampio Provides Update On COVID-19 Program

  • By PR Newswire
  • May 22, 2020 8:00 AM EDT
PRESS RELEASES

Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion™ For COVID-19 Patients

  • By PR Newswire
  • May 11, 2020 8:00 AM EDT
PRESS RELEASES

Ampio Pharmaceutical's Application To The FDA For A Clinical Study Of Ampion™ To Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Featured In FOX News (VIDEO)

  • By PR Newswire
  • Apr 2, 2020 9:00 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.